Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Xatmep,XM2023-001,2023,USA,MDV,350,62,45,55,27.5,32,88,12,25,35,20,20,60,25,10,5,30,35,25,15,5,3,7,4,22,48,35,CMF,AC,TC,FEC,18,15,12,28,55,65,15,45,40,60,2
Xatmep,XM2023-002,2023,Canada,Claim Database,420,68,52,48,28.1,28,85,15,20,30,25,25,55,30,10,5,25,30,30,18,6,4,8,5,25,52,40,AC-T,EC,Docetaxel,Taxol,20,18,14,30,60,70,20,50,30,65,3
Xatmep,XM2023-003,2023,UK,MDV,280,70,48,52,26.9,35,82,10,30,40,15,15,65,20,10,5,35,40,15,20,8,5,10,6,20,45,30,FEC-T,ECF,Carboplatin,Gemcitabine,22,20,16,32,65,75,10,60,30,70,2.5
Xatmep,XM2023-004,2023,Germany,Claim Database,480,65,55,45,27.8,30,86,13,22,38,18,22,58,28,9,5,28,32,28,16,7,3.5,7.5,4.5,23,50,38,PET,TECF,Doxorubicin,Cyclophosphamide,19,17,13,29,58,68,12,48,40,62,2.8
